Tislelizumab
Jun 03, 2024
Rapid Global Expansion of Chinese PD-1/PD-L1 Key Players
Immune checkpoint inhibitors (ICIs) are currently among the most widely used treatments for cancer. Chinese pharmaceutical companies have been making significant strides in developing PD-1 and PD-L1 inhibitors, used to treat various cancers. Several of these companies are now entering or planning to enter the US an...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
